1
|
Jose J, Mandalay A, Cholenahally MN, Khandenahally RS, Budnur SC, Parekh M, Rao RS, Seth A, Chandra P, Kapoor R, Agarwal P, Mathur A, Kumar V, Kanchanahalli SS, Mullasari AS, Subban V, Khanolkar UB, Mehrotra S, Chopra M, Jain RK, Mehta H, Gupta R, Kumar V, Raghuraman B, Shastri N, Elzomor H, Soliman O, Gunasekaran S. Safety and effectiveness of the novel Myval Octacor transcatheter heart valve in severe, symptomatic aortic valve stenosis - A real-world Indian experience (The OCTACOR India Study). CARDIOVASCULAR REVASCULARIZATION MEDICINE 2024; 63:1-7. [PMID: 38423848 DOI: 10.1016/j.carrev.2024.01.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2023] [Revised: 01/15/2024] [Accepted: 01/24/2024] [Indexed: 03/02/2024]
Abstract
PURPOSE To evaluate the safety and effectiveness of the novel, next-generation Myval Octacor - Transcatheter Heart Valve (THV) in patients with severe, symptomatic, native aortic stenosis (AS). METHODS This multicenter, real-world observational registry included 123 patients with severe symptomatic AS, across 16 Indian centers who underwent treatment with the novel Myval Octacor THV. Study endpoints included all-cause mortality, all stroke, acute kidney injury (AKI), major vascular complications, moderate or severe paravalvular leakage (PVL) and new permanent pacemaker implantation (PPI) until 30 days follow-up. RESULTS Of the 123 patients (average age 70.07 ± 8.33 years), 37.4 % (n = 46) were female and 39.84 % presented with bicuspid valves. The technical success rate of the procedure was 100 % and the device success rate at 30 days was 98.4 %. At 30 days (n = 123) after the procedure, the overall mortality was 1.6 %. AKI occurred in 1.6 % of patients and there was no incidence of stroke, bleeding (types 3 and 4), and major vascular complications. In an analysis of 31 patients whose echocardiographic parameters were available across all timepoints, there were significant improvements in the mean pressure gradient (54.31 ± 18.19 mmHg vs. 10.42 ± 4.24 mmHg; p < 0.0001) and effective orifice area (0.66 ± 0.21 cm2 vs. 1.80 ± 0.44 cm2; p < 0.0001) from baseline to the 30-day follow-up. None of the patients experienced severe PVL, while moderate PVL was observed in two patients (1.6 %). CONCLUSIONS Early outcomes of the next-generation, novel Myval Octacor THV proved its safety and effectiveness in the treatment of severe AS.
Collapse
Affiliation(s)
- John Jose
- Christian Medical College and Hospital, Vellore, Tamil Nadu, India
| | | | - Manjunath N Cholenahally
- Sri Jayadeva Institute of Cardiovascular Sciences and Research, Bangalore, Karnataka, India; Sri Jayadeva Institute of Cardiovascular Sciences and Research, Mysore, Karnataka, India
| | | | - Srinivas C Budnur
- Sri Jayadeva Institute of Cardiovascular Sciences and Research, Bangalore, Karnataka, India; Sri Jayadeva Institute of Cardiovascular Sciences and Research, Mysore, Karnataka, India
| | - Maulik Parekh
- Sir H N Reliance Foundation Hospital, Mumbai, Maharashtra, India
| | | | - Ashok Seth
- Fortis Escorts Heart Institute, New Delhi, India
| | - Praveen Chandra
- Medanta-The Medicity Multi-Speciality Hospital, Gurgaon, Haryana, India
| | - Rajneesh Kapoor
- Medanta-The Medicity Multi-Speciality Hospital, Gurgaon, Haryana, India
| | | | - Atul Mathur
- Fortis Escorts Heart Institute, New Delhi, India
| | - Vijay Kumar
- Fortis Escorts Heart Institute, New Delhi, India
| | - Sadananda S Kanchanahalli
- Sri Jayadeva Institute of Cardiovascular Sciences and Research, Bangalore, Karnataka, India; Sri Jayadeva Institute of Cardiovascular Sciences and Research, Mysore, Karnataka, India
| | | | | | | | - Sanjay Mehrotra
- Narayana Multispeciality Hospital, Bangalore, Karnataka, India
| | - Manik Chopra
- Narayana Multispeciality Hospital, Ahmedabad, Gujarat, India
| | - Rajendra K Jain
- Krishna Institute of Medical Sciences (KIMS), Hyderabad, Telangana, India
| | - Haresh Mehta
- S.L. Raheja Hospital, Mumbai, Maharashtra, India
| | | | - Viveka Kumar
- Max Super Speciality Hospital, Saket, New Delhi, India
| | | | | | - Hesham Elzomor
- Discipline of Cardiology, Saolta Group, Galway University Hospital, Health Service Executive and CORRIB Core Lab, University of Galway, H91 V4AY Galway, Ireland
| | - Osama Soliman
- Discipline of Cardiology, Saolta Group, Galway University Hospital, Health Service Executive and CORRIB Core Lab, University of Galway, H91 V4AY Galway, Ireland
| | | |
Collapse
|
2
|
Baumbach A, van Royen N, Amat-Santos IJ, Hudec M, Bunc M, Ijsselmuiden A, Laanmets P, Unic D, Merkely B, Hermanides RS, Ninios V, Protasiewicz M, Rensing BJWM, Martin PL, Feres F, De Sousa Almeida M, van Belle E, Linke A, Ielasi A, Montorfano M, Webster M, Toutouzas K, Teiger E, Bedogni F, Voskuil M, Pan M, Angerås O, Kim WK, Rothe J, Kristić I, Peral V, Garg S, Elzomor H, Tobe A, Morice MC, Onuma Y, Soliman O, Serruys PW. LANDMARK comparison of early outcomes of newer-generation Myval transcatheter heart valve series with contemporary valves (Sapien and Evolut) in real-world individuals with severe symptomatic native aortic stenosis: a randomised non-inferiority trial. Lancet 2024:S0140-6736(24)00821-3. [PMID: 38795719 DOI: 10.1016/s0140-6736(24)00821-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/14/2024] [Revised: 04/10/2024] [Accepted: 04/18/2024] [Indexed: 05/28/2024]
Abstract
BACKGROUND Transcatheter aortic valve implantation is an established, guideline-endorsed treatment for severe aortic stenosis. Precise sizing of the balloon-expandable Myval transcatheter heart valve (THV) series with the aortic annulus is facilitated by increasing its diameter in 1·5 mm increments, compared with the usual 3 mm increments in valve size. The LANDMARK trial aimed to show non-inferiority of the Myval THV series compared with the contemporary THVs Sapien Series (Edwards Lifesciences, Irvine, CA, USA) or Evolut Series (Medtronic, Minneapolis, MN, USA). METHODS In this prospective, multinational, randomised, open-label, non-inferiority trial across 31 hospitals in 16 countries (Germany, France, Sweden, the Netherlands, Italy, Spain, New Zealand, Portugal, Greece, Hungary, Poland, Slovakia, Slovenia, Croatia, Estonia, and Brazil), 768 participants with severe symptomatic native aortic stenosis were randomly assigned (1:1) to the Myval THV or a contemporary THV. Eligibility was primarily decided by the heart team in accordance with 2021 European Society of Cardiology guidelines. As per the criteria of the third Valve Academic Research Consortium, the primary endpoint at 30 days was a composite of all-cause mortality, all stroke, bleeding (types 3 and 4), acute kidney injury (stages 2-4), major vascular complications, moderate or severe prosthetic valve regurgitation, and conduction system disturbances resulting in a permanent pacemaker implantation. Non-inferiority of the study device was tested in the intention-to-treat population using a non-inferiority margin of 10·44% and assuming an event rate of 26·10%. This trial is registered with ClinicalTrials.gov, NCT04275726, and EudraCT, 2020-000137-40, and is closed to new participants. FINDINGS Between Jan 6, 2021, and Dec 5, 2023, 768 participants with severe symptomatic native aortic stenosis were randomly assigned, 384 to the Myval THV and 384 to a contemporary THV. 369 (48%) participants had their sex recorded as female, and 399 (52%) as male. The mean age of participants was 80·0 years (SD 5·7) for those treated with the Myval THV and 80·4 years (5·4) for those treated with a contemporary THV. Median Society of Thoracic Surgeons scores were the same in both groups (Myval 2·6% [IQR 1·7-4·0] vs contemporary 2·6% [1·7-4·0]). The primary endpoint showed non-inferiority of the Myval (25%) compared with contemporary THV (27%), with a risk difference of -2·3% (one-sided upper 95% CI 3·8, pnon-inferiority<0·0001). No significant difference was seen in individual components of the primary composite endpoint. INTERPRETATION In individuals with severe symptomatic native aortic stenosis, the Myval THV met its primary endpoint at 30 days. FUNDING Meril Life Sciences.
Collapse
Affiliation(s)
- Andreas Baumbach
- Centre for Cardiovascular Medicine and Devices, William Harvey Research Institute, Queen Mary University of London and Barts Heart Centre, London, UK
| | - Niels van Royen
- Department of Cardiology, Radboud University Hospital, Nijmegen, Netherlands
| | - Ignacio J Amat-Santos
- Department of Cardiology, University Clinical Hospital of Valladolid, Valladolid, Spain
| | - Martin Hudec
- Department of Acute Cardiology, Middle-Slovak Institute Of Cardiovascular Diseases, Banska Bystrica, Slovakia
| | - Matjaz Bunc
- Department of Cardiology, University Medical Centre Ljubljana, Ljubljana, Slovenia
| | | | - Peep Laanmets
- Department of Invasive Cardiology, North Estonia Medical Centre, Tallinn, Estonia
| | - Daniel Unic
- Department of Cardiac and Transplant Surgery, University Hospital Dubrava, Zagreb, Croatia
| | - Bela Merkely
- Heart and Vascular Centre, Semmelweis University Heart and Vascular Centre, Budapest, Hungary
| | | | - Vlasis Ninios
- Department of Cardiology, European Interbalkan Medical Center, Thessaloniki, Greece
| | - Marcin Protasiewicz
- Department of Cardiology, Institute of Heart Diseases, Wrocław Medical University, Wrocław, Poland
| | | | - Pedro L Martin
- Department of Interventional Cardiology, University Hospital of Gran Canaria Dr Negrín, Las Palmas, Spain
| | - Fausto Feres
- Department of Invasive Cardiology, Instituto Dante Pazzanese, Sao Paulo, Brazil
| | | | - Eric van Belle
- Department of Interventional Cardiology, Lille University, Lille, France
| | - Axel Linke
- Department of Internal Medicine and Cardiology, University Clinic, Heart Center Dresden, University of Technology Dresden, Dresden, Germany
| | - Alfonso Ielasi
- Department of Interventional Cardiology, IRCCS Galeazzi Sant'Ambrogio Hospital, Milan, Italy
| | - Matteo Montorfano
- School of Medicine, Vita-Salute San Raffaele University, Milan, Italy; Interventional Cardiology Unit IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Mark Webster
- Department of Cardiology, Auckland City Hospital, Auckland, New Zealand
| | | | - Emmanuel Teiger
- Department of Medico-surgical Cardiovascular and Anaesthesiology, Henri-Mondor University Hospital, Creteil, France
| | - Francesco Bedogni
- Department of Clinical Cardiology, San Donato Hospital, Milan, Italy
| | - Michiel Voskuil
- Department of Interventional Cardiology, University Medical Center Utrecht, Utrecht, Netherlands
| | - Manuel Pan
- Department of Cardiology, University Hospital Reina Sofía, University of Córdoba, Córdoba, Spain
| | - Oskar Angerås
- Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden; Department of Clinical and Molecular Medicine, Gothenburg University, Gothenburg, Sweden
| | - Won-Keun Kim
- Department of Cardiology and Angiology, University of Giessen and Marburg, Giessen, Germany; Department of Cardiology, Kerckhoff Heart Center, Bad Nauheim, Germany
| | - Jürgen Rothe
- Department of Cardiology and Angiology, University Heart Center Freiburg Bad Krozingen, University Medical Center Freiburg, Freiburg, Germany; Department of Cardiology and Angiology, Faculty of Medicine, University of Freiburg, Freiburg, Germany
| | - Ivica Kristić
- Department of Cardiology, University Hospital of Split, Split, Croatia
| | - Vicente Peral
- Department of Cardiology, Son Espases University Hospital, Palma, Spain
| | - Scot Garg
- Department of Cardiology, Royal Blackburn Hospital, Blackburn, UK
| | - Hesham Elzomor
- Department of Cardiology, School of Medicine, University of Galway, Galway, Ireland
| | - Akihiro Tobe
- Department of Cardiology, School of Medicine, University of Galway, Galway, Ireland
| | | | - Yoshinobu Onuma
- Department of Cardiology, School of Medicine, University of Galway, Galway, Ireland
| | - Osama Soliman
- Department of Cardiology, School of Medicine, University of Galway, Galway, Ireland
| | - Patrick W Serruys
- Department of Cardiology, School of Medicine, University of Galway, Galway, Ireland.
| |
Collapse
|
3
|
Amat-Santos IJ, García-Gómez M. SAPIEN 3 Ultra Resilia: Critical Reflections on Real-World Performance. JACC Cardiovasc Interv 2024; 17:1045-1046. [PMID: 38658118 DOI: 10.1016/j.jcin.2024.03.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/01/2024] [Accepted: 03/04/2024] [Indexed: 04/26/2024]
Affiliation(s)
- Ignacio J Amat-Santos
- Servicio de Cardiología, Hospital Clínico Universitario de Valladolid, Valladolid, Spain; Centro de Investigación Biomédica en Red-Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain.
| | - Mario García-Gómez
- Servicio de Cardiología, Hospital Clínico Universitario de Valladolid, Valladolid, Spain; Centro de Investigación Biomédica en Red-Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain
| |
Collapse
|
4
|
Moscarella E, Ielasi A, Montonati C, Pellegrini D, Pellicano M, Briguglia D, D'Alessandro V, Giannini F, Gamardella M, Medda M, Guagliumi G, Banfi C, Glauber M, Tespili M. Comparing two-year outcomes of balloon-expandable Myval and self-expanding Evolut R in severe aortic valve stenosis. Int J Cardiol 2024; 400:131701. [PMID: 38168557 DOI: 10.1016/j.ijcard.2023.131701] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/13/2023] [Revised: 12/07/2023] [Accepted: 12/29/2023] [Indexed: 01/05/2024]
Abstract
BACKGROUND The new balloon-expandable (BE) Myval transcatheter heart valves (THV) has shown promising early results with low paravalvular leak (PVL) and permanent pacemaker implantation (PPI) rates. Limited data are available regarding its long-term performance. We aimed to compare the 2-year clinical and echocardiographic outcomes of transcatheter aortic valve replacement (TAVR) using the self-expanding (SE) Evolut R and the BE Myval THVs. METHODS The EVAL study included 166 patients with severe aortic valve stenosis who underwent TAVR either with SE Evolut R (n = 108) or BE Myval (n = 58) THV. Primary objectives include comparison on clinical efficacy (freedom from all-cause mortality, stroke, and cardiovascular hospitalization), echocardiographic performance and PPI rates between the two THVs. RESULTS At 2-year the BE Myval group showed higher clinical efficacy (86% vs. 66%,HR:2.62, 95%CI 2.2-5.1;p = 0.006), with fewer cardiac hospitalizations (3.4% vs. 13.9%,p = 0.03). No significant differences in all-cause mortality, cardiovascular mortality, or stroke rates were observed. The proportion of patients with ≥moderate PVL was significantly lower in the BE Myval compared to the SE Evolut R group (4%vs. 22%,p = 0.008). The mean transvalvular gradient was significantly higher in the SE group compared to the BE group (9.5 ± 4.3 vs. 6.9 ± 2.2 mmHg,p < 0.001), however there was no difference in the percentage of patients with a mean gradient ≥20 mmHg between the two groups. CONCLUSIONS Both THVs offer similar 2-year clinical outcomes. The BE Myval THV demonstrated advantages with higher clinical efficacy and lower PVL incidence. Longer follow-up and randomized trials are needed to validate these results and assess Myval's sustained performance and durability.
Collapse
Affiliation(s)
- Elisabetta Moscarella
- Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy
| | - Alfonso Ielasi
- U.O. Cardiologia Ospedaliera, IRCCS Ospedale Galeazzi Sant'Ambrogio, Milan, Italy.
| | - Carolina Montonati
- U.O. Cardiologia Ospedaliera, IRCCS Ospedale Galeazzi Sant'Ambrogio, Milan, Italy
| | - Dario Pellegrini
- U.O. Cardiologia Ospedaliera, IRCCS Ospedale Galeazzi Sant'Ambrogio, Milan, Italy
| | - Mariano Pellicano
- U.O. Cardiologia Ospedaliera, IRCCS Ospedale Galeazzi Sant'Ambrogio, Milan, Italy
| | - Daniele Briguglia
- U.O. Cardiologia Ospedaliera, IRCCS Ospedale Galeazzi Sant'Ambrogio, Milan, Italy
| | | | - Francesco Giannini
- U.O. Cardiologia Ospedaliera, IRCCS Ospedale Galeazzi Sant'Ambrogio, Milan, Italy
| | - Marco Gamardella
- U.O. Cardiologia Ospedaliera, IRCCS Ospedale Galeazzi Sant'Ambrogio, Milan, Italy; Università Vita Salute San Raffaele, Milan, Italy
| | - Massimo Medda
- U.O. Cardiologia Ospedaliera, IRCCS Ospedale Galeazzi Sant'Ambrogio, Milan, Italy
| | - Giulio Guagliumi
- U.O. Cardiologia Ospedaliera, IRCCS Ospedale Galeazzi Sant'Ambrogio, Milan, Italy
| | - Carlo Banfi
- U.O. Cardiochirurgia Universitaria, IRCCS Ospedale Galeazzi Sant'Ambrogio, Milan, Italy; Geneva Hemodynamic Research Group, Geneva, Switzerland
| | - Mattia Glauber
- Faculty of Medicine, University of Geneva, Switzerland; U.O. Cardiochirurgia Mini-Invasiva, IRCCS Ospedale Galeazzi Sant'Ambrogio, Milan, Italy
| | - Maurizio Tespili
- U.O. Cardiologia Ospedaliera, IRCCS Ospedale Galeazzi Sant'Ambrogio, Milan, Italy
| |
Collapse
|
5
|
Kilic T, Ielasi A, Ninios V, Korkmaz L, Panagiotakos D, Yerlikaya G, Ozderya A, Montonati C, Tespili M, Coskun S, Sahin T, Ninios I, Vlasopoulou K, Konus AH, Kul S, Akyuz AR. Clinical outcomes of the Myval transcatheter heart valve system in patients with severe aortic valve stenosis: a two-year follow-up observational study. Arch Med Sci 2024; 20:410-419. [PMID: 38757027 PMCID: PMC11094825 DOI: 10.5114/aoms/176937] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/04/2023] [Accepted: 12/13/2023] [Indexed: 05/18/2024] Open
Abstract
Introduction Limited data exist on long-term follow-up of severe aortic stenosis (SAS) patients who have undergone transcatheter aortic valve implantation (TAVI) with a new generation, balloon expandable Myval transcatheter heart valve (THV). Thus, we sought to investigate the performance and 2-year clinical outcome of the Myval THV system based on Valve Academic Research Consortium-3 (VARC-3) criteria. Material and methods A multi-centre, registry-based, observational study was conducted, which included 207 consecutive degenerative SAS patients, from Turkey (n = 128), Italy (n = 58), and Greece (n = 21) (mean [standard deviation] 81 (7) years, 94 [45%] men; 73% NYHA III or IV; EuroSCORE II 5.2% [2.4%]); all patients underwent TAVI with Myval. Patients were followed up at 1 year and 2 years after implantation. Clinical and procedural outcomes were defined according to VARC-3 criteria. Results Technical success was observed in 204 (99%), device success was observed in 189 (91%), early safety was observed in 161 (78%), and clinical efficacy was observed in 163 (79%) patients. The 30-day death rate was 7.7%; of these, 3.4% were due to cardiovascular reasons. All-cause and cardiovascular mortality rates were 9.7% and 4.3% at 1-year follow-up, and 17.4% and 9.7% at 2-year follow-up, respectively. Incidence of ≥ moderate paravalvular leak (PVL) at 30 days, 1 year and 2 years of follow-up were 3.4%, 4.3% and 4.8%. A total of 11.1% of patients required a permanent pacemaker implantation (PPI) at 30 days after implantation, while the cumulative rate of PPI at 2 years was 12.1%. Conclusions In this cohort of patients with SAS, the Myval was found to be safe and effective in up to 2 years of follow-up.
Collapse
Affiliation(s)
- Teoman Kilic
- Department of Cardiology, Medical Faculty, Kocaeli University, Kocaeli, Turkey
| | - Alfonso Ielasi
- U.O. Cardiologia Ospedalirea, IRCCSOspedale Galeazzi Sant’Ambrogio, Italy
| | - Vlasis Ninios
- Department of Cardiology, Interbalkan European Medical Center, Thessaloniki, Greece
| | - Levent Korkmaz
- Department of Cardiology, University of Health Sciences, Trabzon Ahi Evren Cardiovascular and Thoracic Surgery Training and Research Hospital, Turkey
| | | | - Gokhan Yerlikaya
- Department of Cardiology, University of Health Sciences, Trabzon Ahi Evren Cardiovascular and Thoracic Surgery Training and Research Hospital, Turkey
| | - Ahmet Ozderya
- Department of Cardiology, University of Health Sciences, Trabzon Ahi Evren Cardiovascular and Thoracic Surgery Training and Research Hospital, Turkey
| | - Carolina Montonati
- U.O. Cardiologia Ospedalirea, IRCCSOspedale Galeazzi Sant’Ambrogio, Italy
| | - Maurizio Tespili
- U.O. Cardiologia Ospedalirea, IRCCSOspedale Galeazzi Sant’Ambrogio, Italy
| | - Senol Coskun
- Department of Cardiology, Medical Faculty, Kocaeli University, Kocaeli, Turkey
| | - Tayfun Sahin
- Department of Cardiology, Medical Faculty, Kocaeli University, Kocaeli, Turkey
| | - Ilias Ninios
- Department of Cardiology, Interbalkan European Medical Center, Thessaloniki, Greece
| | - Konstantina Vlasopoulou
- Department of Cardiology, National and Kapodistrian University of Athens, Hippokration General Hospital, Athens, Greece
| | - Ali Hakan Konus
- Department of Cardiology, University of Health Sciences, Trabzon Ahi Evren Cardiovascular and Thoracic Surgery Training and Research Hospital, Turkey
| | - Selim Kul
- Department of Cardiology, University of Health Sciences, Trabzon Ahi Evren Cardiovascular and Thoracic Surgery Training and Research Hospital, Turkey
| | - Ali Riza Akyuz
- Department of Cardiology, University of Health Sciences, Trabzon Ahi Evren Cardiovascular and Thoracic Surgery Training and Research Hospital, Turkey
| |
Collapse
|
6
|
Magyari B, Kittka B, Goják I, Kasza G, Schönfeld K, Szapáry LB, Simon M, Kiss R, Bertalan A, Várady E, Gyimesi A, Szokodi I, Horváth I. Single center experience with the balloon-expandable Myval transcatheter aortic valve system with the first 100 patients: 30-day and 1-year follow-up. Catheter Cardiovasc Interv 2023; 102:1317-1330. [PMID: 37870123 DOI: 10.1002/ccd.30868] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/29/2023] [Revised: 09/07/2023] [Accepted: 10/03/2023] [Indexed: 10/24/2023]
Abstract
AIMS To report our single-center data, regarding the first 100 patients who underwent TAVR procedure with the new balloon-expandable MYVAL system. We report 30-day and 1-year outcomes in low to high-risk TAVR patient population. METHODS From November 2019 to July 2021, 100 consecutive patients underwent TAVR procedure. Patient outcome was classified according to the VARC-2 definitions. The device performance was assessed using transthoracic echocardiography. Data collection was allowed by the Local Ethical Committee. RESULTS The mean age was 74.7 years, 63 (63%) were male. The mean Euroscore II and STS score were 4.8 ± 4.9 and 5.6 ± 3.9, respectively. Transfemoral access was the most frequent (surgical vs. percutaneous 2% vs. 97%) and in one patient surgical subclavian access was used. VARC-2 outcomes were as follows: device success 99%, STROKE 1%, major and minor vascular complication was 1% and 11%, respectively, the rate of new permanent pacemaker implantation was 30.7%. At discharge, the incidence of grade I, grade II aortic regurgitation was 39% and 1%, respectively, without relevant PVL. In-hospital mortality was only 1%. These results included a high proportion (17%) of patients with bicuspid aortic valves. At 1 year, the all-cause mortality rate was 7% (only two due to cardiac event) and only a single patient had valve-related dysfunction requiring surgical aortic replacement. CONCLUSIONS TAVR procedure with MYVAL transcatheter heart valve system shows excellent 30-day and 1-year outcomes regarding patient survival, technical success, and valve-related adverse events. The limitations of our study comprise a single-center study with retrospective data collection.
Collapse
Affiliation(s)
- Balázs Magyari
- Heart Institute, Medical School, University of Pécs, Pécs, Hungary
- Szentágothai Research Centre, University of Pécs, Pécs, Hungary
| | - Bálint Kittka
- Heart Institute, Medical School, University of Pécs, Pécs, Hungary
- Szentágothai Research Centre, University of Pécs, Pécs, Hungary
| | - Ilona Goják
- Heart Institute, Medical School, University of Pécs, Pécs, Hungary
| | - Gábor Kasza
- Department of Vascular Surgery, Medical School, University of Pécs, Pécs, Hungary
| | - Kristóf Schönfeld
- Heart Institute, Medical School, University of Pécs, Pécs, Hungary
- Szentágothai Research Centre, University of Pécs, Pécs, Hungary
| | - László Botond Szapáry
- Heart Institute, Medical School, University of Pécs, Pécs, Hungary
- Szentágothai Research Centre, University of Pécs, Pécs, Hungary
| | - Mihály Simon
- Heart Institute, Medical School, University of Pécs, Pécs, Hungary
- Szentágothai Research Centre, University of Pécs, Pécs, Hungary
| | - Rudolf Kiss
- Heart Institute, Medical School, University of Pécs, Pécs, Hungary
| | - Andrea Bertalan
- Heart Institute, Medical School, University of Pécs, Pécs, Hungary
| | - Edit Várady
- Department of Medical Imaging, Medical School, University of Pécs, Pécs, Hungary
| | - András Gyimesi
- EconNet Research Group, Faculty of Business and Economics, University of Pécs, Pécs, Hungary
| | - István Szokodi
- Heart Institute, Medical School, University of Pécs, Pécs, Hungary
- Szentágothai Research Centre, University of Pécs, Pécs, Hungary
| | - Iván Horváth
- Heart Institute, Medical School, University of Pécs, Pécs, Hungary
- Szentágothai Research Centre, University of Pécs, Pécs, Hungary
| |
Collapse
|
7
|
Halim J, den Heijer P, van den Branden B, Meuwissen M, Vos J, Schölzel B, IJsselmuiden A. Short-term outcome after transcatheter aortic valve replacement with a novel balloon-expandable valve. Neth Heart J 2023; 31:500-505. [PMID: 36480146 PMCID: PMC10667167 DOI: 10.1007/s12471-022-01738-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/28/2022] [Indexed: 12/13/2022] Open
Abstract
OBJECTIVES Transcatheter aortic valve replacement (TAVR) has been expanding rapidly with numerous transcatheter heart valve (THV) systems currently available. The Myval balloon-expandable (BE) valve (Meril Life Sciences Pvt. Ltd., India) is a novel THV system indicated for the treatment of patients with severe aortic stenosis. The primary objective of this study is to assess the safety and performance of the Myval BE valve. METHODS In this prospective single-centre study, 120 consecutive patients who underwent TAVR with the Myval BE valve were included. Clinical outcomes were evaluated at 30 days and 6 months using Valve Academic Research Consortium‑2 criteria. All-cause mortality, stroke, acute kidney injury, major vascular complications, moderate or severe paravalvular leakage (PVL) and need for a permanent pacemaker implantation (PPI) were investigated. RESULTS At 6‑month follow-up, all-cause death and cardiac death were seen in 5.8% and 0.8% of the patients respectively. Periprocedural stroke and need for PPI were both seen in 3.3% of the patients. Access-site-related vascular and bleeding complications were absent. Improved valve haemodynamics and no moderate to severe PVL could be seen at 30 days. An intermediate valve size was selected in 51% of the patients. CONCLUSIONS The Myval BE valve demonstrates improved valve haemodynamics, absence of moderate to severe PVL and good safety outcomes at 6‑month follow-up with low cardiac death rate and acceptable rates of permanent pacemaker implantation and periprocedural stroke. Future randomised controlled trials will further establish the clinical utility of the Myval BE valve.
Collapse
Affiliation(s)
- J Halim
- Department of Cardiology, Amphia Hospital Breda, Breda, The Netherlands.
| | - P den Heijer
- Department of Cardiology, Amphia Hospital Breda, Breda, The Netherlands
| | - B van den Branden
- Department of Cardiology, Amphia Hospital Breda, Breda, The Netherlands
| | - M Meuwissen
- Department of Cardiology, Amphia Hospital Breda, Breda, The Netherlands
| | - J Vos
- Department of Cardiology, Amphia Hospital Breda, Breda, The Netherlands
| | - B Schölzel
- Department of Cardiology, Amphia Hospital Breda, Breda, The Netherlands
| | - A IJsselmuiden
- Department of Cardiology, Amphia Hospital Breda, Breda, The Netherlands
| |
Collapse
|
8
|
Amat-Santos IJ, García-Gómez M, de Marco F, Won-Keun K, Brito J, Halim J, Jose J, Sengotuvelu G, Seth A, Terkelsen C, Protasiewicz M, Bonilla N, García B, Sánchez-Luna JP, Blasco-Turrión S, González JC, González-Bartol E, Ijsselmuiden AJJ, Gómez-Salvador I, Carrasco Moraleja M, San Román A. Latest-iteration balloon- and self-expandable transcatheter valves for severe bicuspid aortic stenosis: the TRITON study. REVISTA ESPANOLA DE CARDIOLOGIA (ENGLISH ED.) 2023; 76:872-880. [PMID: 36898524 DOI: 10.1016/j.rec.2023.03.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/04/2022] [Accepted: 02/09/2023] [Indexed: 03/11/2023]
Abstract
INTRODUCTION AND OBJECTIVES No comparisons have been published yet regarding the newest iteration of balloon- and self-expandable transcatheter heart valves for the treatment of bicuspid aortic valve (BAV) stenosis. METHODS Multicenter registry of consecutive patients with severe BAV stenosis treated with balloon-expandable transcatheter heart valves (Myval and SAPIEN 3 Ultra, S3U) or self-expanding Evolut PRO+(EP+). TriMatch analysis was carried out to minimize the impact of baseline differences. The primary endpoint of the study was 30-day device success, and the secondary endpoints were the composite and individual components of early safety at 30 days. RESULTS A total of 360 patients (age 76.6±7.6 years, 71.9% males) were included: 122 Myval (33.9%), 129 S3U (35.8%), and 109 EP+(30.3%). The mean STS score was 3.6±1.9%. There were no cases of coronary artery occlusion, annulus rupture, aortic dissection, or procedural death. The primary endpoint of device success at 30 days was significantly higher in the Myval group (Myval: 100%; S3U: 87.5%; and EP+: 81.3%), mainly due to higher residual aortic gradients with S3U and greater≥moderate aortic regurgitation (AR) with EP+. No significant differences were found in the unadjusted rate of pacemaker implantation. CONCLUSIONS In patients with BAV stenosis deemed unsuitable for surgery, Myval, S3U and EP+showed similar safety but balloon-expandable Myval had better gradients than S3U, and both balloon-expandable devices had lower residual AR than EP+, suggesting that, taking into consideration the patient-specific risks, any of these devices can be selected with optimal outcomes.
Collapse
Affiliation(s)
- Ignacio J Amat-Santos
- Departamento de Cardiología, Hospital Clínico Universitario de Valladolid, Valladolid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, Spain.
| | - Mario García-Gómez
- Departamento de Cardiología, Hospital Clínico Universitario de Valladolid, Valladolid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, Spain
| | | | - Kim Won-Keun
- Cardiology Department, Kerckhoff-Klinik, Bad Nauheim, Germany
| | - Joao Brito
- Cardiology Department, Hospital Santa Cruz, Lisbon, Portugal
| | - Jonathan Halim
- Cardiology Department, Amphia Hospital, Breda, The Netherlands
| | - John Jose
- Cardiology Department, Christian Medical College Vellore, Tamil Nadu, India
| | | | - Ashok Seth
- Cardiology Department, Fortis Escorts Heart Institute, New Delhi Hospital, Delhi, India
| | | | - Marcin Protasiewicz
- Cardiology Department, Institute of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland
| | - Nelson Bonilla
- Departamento de Cardiología, Hospital Médico Quirúrgico, Instituto Salvadoreño del Seguro Social, San Salvador, El Salvador
| | - Bruno García
- Departamento de Cardiología, Hospital Universitario Vall d'Hebron, Barcelona, Spain
| | - Juan Pablo Sánchez-Luna
- Departamento de Cardiología, Hospital Clínico Universitario de Valladolid, Valladolid, Spain
| | - Sara Blasco-Turrión
- Departamento de Cardiología, Hospital Clínico Universitario de Valladolid, Valladolid, Spain
| | - José Carlos González
- Departamento de Cardiología, Hospital Clínico Universitario de Valladolid, Valladolid, Spain
| | - Esther González-Bartol
- Departamento de Cardiología, Hospital Clínico Universitario de Valladolid, Valladolid, Spain
| | | | - Itziar Gómez-Salvador
- Departamento de Cardiología, Hospital Clínico Universitario de Valladolid, Valladolid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, Spain
| | - Manuel Carrasco Moraleja
- Departamento de Cardiología, Hospital Clínico Universitario de Valladolid, Valladolid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, Spain
| | - Alberto San Román
- Departamento de Cardiología, Hospital Clínico Universitario de Valladolid, Valladolid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, Spain
| |
Collapse
|
9
|
Jimenez-Quevedo P, Espejo-Paeres C, Hennessey B. Bicuspid aortic valve: one of the last remaining challenges for the percutaneous treatment of aortic valve disease. REVISTA ESPANOLA DE CARDIOLOGIA (ENGLISH ED.) 2023; 76:843-844. [PMID: 37331587 DOI: 10.1016/j.rec.2023.04.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/09/2023] [Accepted: 04/17/2023] [Indexed: 06/20/2023]
Affiliation(s)
- Pilar Jimenez-Quevedo
- Servicio de Cardiología, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain.
| | | | | |
Collapse
|
10
|
Sanchez-Luna JP, Martín P, Dager AE, Charry PD, Beltrán JR, Sánchez-Recalde Á, Giannini F, Gómez-Menchero A, Pan M, Ielasi A, Monastyrski A, Barbanti M, Fernandez-Avilés F, Ancona MB, Mussayev A, De Brahi JP, Lamelas P, Sánchez-Pérez A, García Puerta M, Ortiz M, Gonzalez-Gutiérrez JC, Marengo G, Gómez J, Gonzalez-Bartol E, Stepanenko A, Gomez-Salvador I, San Román JA, Amat-Santos IJ. Clinical outcomes of TAVI with the Myval balloon-expandable valve for non-calcified aortic regurgitation. EUROINTERVENTION 2023; 19:580-588. [PMID: 37565470 PMCID: PMC10500190 DOI: 10.4244/eij-d-23-00344] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/02/2023] [Accepted: 06/20/2023] [Indexed: 08/12/2023]
Abstract
BACKGROUND Transcatheter aortic valve replacement (TAVR) in non-calcified aortic regurgitation (NCAR) is an off-label procedure. The balloon-expandable Myval includes extra-large sizes (30.5 mm and 32 mm) of interest in this setting. AIMS We aimed to evaluate the safety and feasibility of Myval in NCAR. METHODS This was an international, multicentre, observational study that enrolled all consecutive patients with symptomatic severe NCAR undergoing TAVR with the Myval device. The images were centrally analysed. RESULTS A total of 113 patients were recruited, 64.6% were men, the mean age was 78.4±7.5 years, and the Society of Thoracic Surgeons score was 2.7±1.7%. Aortic root dilatation was present in 59.3% of patients, 7.1% were bicuspid, and the mean annular area was 638.6±106.0 mm2. The annular area was beyond the recommended range for extra-large sizes in 2.6% of cases, and additional volume was added in 92% (median 4 cc, up to 9 cc). The extra-large sizes were used in 95 patients (84.1%), and the mean oversizing was 17.9±11.0%. The technical success rate was 94.7%; the rate of residual ≥moderate aortic regurgitation was 8.9%, and the pacemaker rate was 22.2%. There were no cases of annular rupture, cardiac tamponade, or aortic dissection, but in 4 patients (3.5%) valve embolisation occurred (1 antegrade and 3 ventricular), all in cases with a tapered left ventricle outflow tract (p=0.007). Thirty-day and 1-year mortality were 5.3% and 9.7%, respectively. Technical success was associated with better survival (97.1% vs 72.7%; p=0.012), and valve embolisation was the main determinant of mortality (p=0.047). CONCLUSIONS Myval is a feasible and safe option for selected non-operable patients with NCAR and demonstrated good midterm outcomes and lack of impact of oversizing on device durability.
Collapse
Affiliation(s)
| | - Pedro Martín
- Cardiology Department, Hospital Universitario de Gran Canaria Dr Negrin, Las Palmas, Gran Canaria, Spain
| | - Antonio E Dager
- Cardiology Department, Angiografía de Occidente Hospital, Cali, Colombia
| | - Pablo D Charry
- Cardiology Department, Clínica Medilaser, Neiva, Colombia
| | - Javier R Beltrán
- Cardiology Department, Los Comuneros Hospital Universitario de Bucaramanga, Bucaramanga, Colombia
| | | | | | | | - Manuel Pan
- Cardiology Department, Hospital Reina Sofía, Cordoba, Spain and University of Cordoba (IMIBIC), Cordoba, Spain
| | - Alfonso Ielasi
- Cardiology Department, IRCCS Ospedale Galeazzi Sant'Ambrogio, Milan, Italy
| | - Andrea Monastyrski
- Cardiology Department, Hospital Universitario Val d'Hebron, Barcelona, Spain
| | - Marco Barbanti
- Cardiology Department, Policlinico-Vittorio Emanuele Hospital, Catania, Italy
| | | | | | - Abdurashid Mussayev
- Cardiology Department, National Research Cardiac Surgery Center, Astana, Kazakhstan
| | - Juan Pablo De Brahi
- Cardiology Department, Sanatorio de La Trinidad Mitre, Buenos Aires, Argentina
| | - Pablo Lamelas
- Cardiology Department, Instituto Cardiovascular, Buenos Aires, Argentina
| | - Andrés Sánchez-Pérez
- Cardiology Department, Hospital Universitario de Gran Canaria Dr Negrin, Las Palmas, Gran Canaria, Spain
| | | | - Miguel Ortiz
- Cardiology Department, Angiografía de Occidente Hospital, Cali, Colombia
| | | | - Giorgio Marengo
- Cardiology Department, Hospital Clinico Universitario de Valladolid, Valladolid, Spain
| | - Javier Gómez
- Cardiology Department, Hospital Clinico Universitario de Valladolid, Valladolid, Spain
| | | | - Alexander Stepanenko
- Cardiology Department, Hospital Clinico Universitario de Valladolid, Valladolid, Spain
| | - Itziar Gomez-Salvador
- Centro de Investigación Biomédica en Red, Enfermedades Cardiovasculares, Madrid, Spain
| | - J Alberto San Román
- Cardiology Department, Hospital Clinico Universitario de Valladolid, Valladolid, Spain
- Centro de Investigación Biomédica en Red, Enfermedades Cardiovasculares, Madrid, Spain
| | - Ignacio J Amat-Santos
- Cardiology Department, Hospital Clinico Universitario de Valladolid, Valladolid, Spain
- Centro de Investigación Biomédica en Red, Enfermedades Cardiovasculares, Madrid, Spain
| |
Collapse
|
11
|
Mussayev A, Alimbayev S, Tanaliev N, Kuanyshbek A, Marat A, Lesbekov T, Raissov Y, Sadykova A, Kamila AK, Mukarov M, Pya Y. Case report: Transcatheter tricuspid valve-in-valve implantation using novel balloon-expandable aortic valve with 1 year follow-up. Front Cardiovasc Med 2023; 10:1152280. [PMID: 37485262 PMCID: PMC10361752 DOI: 10.3389/fcvm.2023.1152280] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2023] [Accepted: 06/06/2023] [Indexed: 07/25/2023] Open
Abstract
Generally, the dysfunction or failure of bioprosthetic heart valves (BHVs) is managed by replacement surgery. In the case of tricuspid valve dysfunction, re-do surgery is rarely attempted because of the critically high risk of developing pulmonary hypertension, pulmonary embolism, and intraoperative mortality. Hence, transcatheter tricuspid repair and replacement procedures are preferred. More recently, transcatheter valve-in-valve (ViV) treatments have gained importance because of their less invasiveness, especially for patients with prior surgeries. Encouraging evidence of the safety and effectiveness of a novel balloon-expandable (BE) transcatheter heart valve (THV)-the Myval THV-has been reported for ViV procedures. Here, we present a case-series of 5 patients, in whom tricuspid ViV procedure was performed using BE Myval THV, implanted supra-annularly by anchoring onto the deteriorated BHV. This case-series details the procedural steps to prevent in-hospital adverse events and early (30-day) mortality and the challenges during tricuspid ViV interventions.
Collapse
Affiliation(s)
- Abdurashid Mussayev
- Head of Cathlab, National Research Cardiac Surgery Center, Astana, Kazakhstan
| | - Serik Alimbayev
- Head of Structural Heart Diseases, National Research Cardiac Surgery Center, Astana, Kazakhstan
| | - Nursultan Tanaliev
- Department of Interventional Cardiology, National Research Cardiac Surgery Center, Astana, Kazakhstan
| | - Aidyn Kuanyshbek
- Head of the Department of Anesthesiology, Resuscitation and Intensive Care, National Research Cardiac Surgery Center, Astana, Kazakhstan
| | - Aripov Marat
- Head of Department of Interventional Cardiology, National Research Cardiac Surgery Center, Astana, Kazakhstan
| | - Timur Lesbekov
- Head of the Department of Cardiac Surgery, National Research Cardiac Surgery Center, Astana, Kazakhstan
| | - Yerkezhan Raissov
- Resident of Interventional Cardiology, National Research Cardiac Surgery Center, Astana, Kazakhstan
| | - Aigerim Sadykova
- Chief Nurse of Cathlab, National Research Cardiac Surgery Center, Astana, Kazakhstan
| | - Askarovna Kenzhebayeva Kamila
- Clinical Cardiologist, Central Hospital with a Polyclinic of the Ministry of Internal Affairs, Astana, Republic of Kazakhstan
| | - Murat Mukarov
- Head of the Department of Cardiology, National Research Cardiac Surgery Center, Astana, Kazakhstan
| | - Yuriy Pya
- Department of Cardiac Surgery, National Research Cardiac Surgery Center, Astana, Kazakhstan
| |
Collapse
|
12
|
Seth A, Kumar V, Singh VP, Kumar D, Varma P, Rastogi V. Myval: A Novel Transcatheter Heart Valve for the Treatment of Severe Aortic Stenosis. Interv Cardiol 2023; 18:e12. [PMID: 37398875 PMCID: PMC10311401 DOI: 10.15420/icr.2020.32] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2020] [Accepted: 05/04/2022] [Indexed: 07/04/2023] Open
Abstract
Transcatheter aortic valve implantation (TAVI) performed using femoral arterial access is now a guideline recommended treatment for severe calcific aortic stenosis (AS) in elderly patients. Technological advancements and procedural refinements have focused on making TAVI simpler, safer, more effective and durable. Myval (Meril Lifesciences) is a new generation balloon-expandable transcatheter heart valve (THV) developed in India that possesses novel features to improve deliverability and aid precise deployment. Following the first-in-human study, Myval was approved in India for commercial implantation in October 2018 and was subsequently given a CE mark in April 2019. This article reviews the science, technology and up-to-date clinical evidence for the Myval THV.
Collapse
Affiliation(s)
- Ashok Seth
- Interventional Cardiology and Structural Therapies, Fortis Escorts Heart Institute New Delhi, India
| | - Vijay Kumar
- Interventional Cardiology and Structural Therapies, Fortis Escorts Heart Institute New Delhi, India
| | - Vivudh Pratap Singh
- Interventional Cardiology and Structural Therapies, Fortis Escorts Heart Institute New Delhi, India
| | - Dhananjay Kumar
- Interventional Cardiology and Structural Therapies, Fortis Escorts Heart Institute New Delhi, India
| | - Puneet Varma
- Interventional Cardiology and Structural Therapies, Fortis Escorts Heart Institute New Delhi, India
| | - Vishal Rastogi
- Interventional Cardiology and Structural Therapies, Fortis Escorts Heart Institute New Delhi, India
| |
Collapse
|
13
|
Moscarella E, Ielasi A, Mussayev A, Montorfano M, Mullassari A, Martin P, Testa L, Jose J, Ninios V, Toutouzas K, Giannini F, Kertesz A, Unic D, Nissen H, Ezhumalai B, Senguttuvan NB, Amat-Santos I, Seth A, Bedogni F, Tespili M. Transcatheter valve-in-valve or valve-in-ring implantation with a novel balloon-expandable device in patients with bioprosthetic left side heart valves failure: 1-year follow-up from a multicenter experience. Int J Cardiol 2023; 376:35-45. [PMID: 36657566 DOI: 10.1016/j.ijcard.2023.01.017] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/07/2022] [Revised: 12/29/2022] [Accepted: 01/12/2023] [Indexed: 01/18/2023]
Abstract
BACKGROUND Transcatheter aortic and mitral valve-in-valve (ViV) or valve-in-ring (ViR) implantation into failed bioprosthetic heart valves (BHVs) or rings represents an appealing, less invasive, treatment option for patients at high surgical risk. Nowadays, few data have been reported on the use of balloon-expandable Myval (Meril Life Science, Vapi, India) transcatheter heart valve (THV) for the treatment of degenerated BHVs or rings. We aimed at evaluating the early and mid-term clinical outcomes of patients with left side heart bioprosthesis deterioration treated with transcatheter ViV/ViR implantation using Myval THV. METHODS 97 consecutive patients with symptomatic, severe aortic(n=33) and mitral(n=64) BHVs/ring dysfunction underwent transcatheter aortic ViV and mitral ViV/ViR implantation with Myval THV. RESULTS Technical success was achieved in 95 (98%) of the patients. Two cases of acute structural trans-catheter mitral ViV/ViR dysfunction requiring a second THV implantation were reported. At 30-day, a significant reduction in prosthetic trans-valvular pressure gradients and increase in valve areas were seen following both aortic and mitral ViV/ViR implantation. Overall survival at 15 months (IQR 8-21) was 92%. Patients undergoing mitral ViV/ViR had a relatively worse survival compared with those undergoing aortic ViV implantation (89% vs. 97% respectively; HR:2.7,CI:0.33-22.7;p=0.34). At longest follow-up available a significant improvement in NYHA functional class I and II was observed in patients with aortic and mitral ViV/ViR implantation(93.8% and 92.1%). CONCLUSIONS Despite high surgical risk, transcatheter ViV/ViR implantation for failed left side heart bioprosthesis can be performed safely using Myval THV with a high success rate and low early and mid-term mortality and morbidity.
Collapse
Affiliation(s)
- Elisabetta Moscarella
- Division of Clinical Cardiology, A.O.R.N. "Sant'Anna e San Sebastiano", Caserta, Italy; Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy
| | - Alfonso Ielasi
- Cardiology Division, IRCCS Ospedale Galeazzi-Sant'Ambrogio, Milan, Italy.
| | - Abdurashid Mussayev
- Catheterization Laboratory, National Research Center for Cardiac Surgery, Nur-Sultan, Kazakhstan
| | - Matteo Montorfano
- Interventional Cardiology Unit, IRCCS San Raffaele Scientific Insitute, Milan, Italy
| | | | - Pedro Martin
- Hospital Universitario de Gran Canaria Dr Negrin, Las Palmas, Spain
| | - Luca Testa
- Department of Cardiology, IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy
| | - John Jose
- Department of Cardiology, Christian Medical College & Hospital, Vellore, India
| | - Vlasis Ninios
- Department of Cardiology, Interbalkan European Medical Center, Thessaloniki, Greece
| | - Kostantinos Toutouzas
- First Department of Cardiology, Medical School, National and Kapodistrian University of Athens, Hippocration General Hospital, Athens, Greece
| | | | - Attila Kertesz
- Department of Cardiology and Cardiac Surgery, University of Debrecen, Debrecen, Hungary
| | - Daniel Unic
- Department of Cardiac and Transplant Surgery, University Hospital "Dubrava", Zagreb, Croatia
| | - Henrik Nissen
- Depertment of Cardiology, Odense University Hospital, Odense, Denmark
| | - Babu Ezhumalai
- Department of Cardiology, Fortis Malar Hospital, Adyar, Chennai, India
| | | | - Ignacio Amat-Santos
- CIBERCV, Interventional Cardiology, Hospital Clínico Universitario de Valladolid, Valladolid, Spain
| | - Ashok Seth
- Fortis Escorts Heart Institute, New Delhi, India
| | - Francesco Bedogni
- Department of Cardiology, Christian Medical College & Hospital, Vellore, India
| | - Maurizio Tespili
- Cardiology Division, IRCCS Ospedale Galeazzi-Sant'Ambrogio, Milan, Italy
| |
Collapse
|
14
|
Balloon-Expandable TAVR Bioprostheses: Area or Perimeter Sizing? A Prospective Pilot Study. J Interv Cardiol 2022; 2022:3139476. [DOI: 10.1155/2022/3139476] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2022] [Revised: 09/27/2022] [Accepted: 09/30/2022] [Indexed: 11/17/2022] Open
Abstract
Objective. In TAVR, area sizing is used for balloon-expandable (BE) valves, whereas self-expanding valves are sized to annulus perimeter. For BE valves, this seems illogical: these frames force a circular shape even on an ellipsoid annulus. This can potentially lead to relative undersizing when area sizing is being applied. We developed a perimeter-based sizing algorithm to evaluate the safety and feasibility of perimeter sizing for the Myval BE valve. Methods. In this prospective single-center study, 60 patients with severe aortic stenosis treated with the Myval BE valve were included. Perimeter sizing was used with limited oversizing of 3.7% ± 1.3% compared to the annulus perimeter. After TAVR, clinical outcomes were evaluated at 30 days and 1 year. An echocardiographic follow-up took place at 30 days. Results. At 30 days, the need for PPI and stroke occurred in 2% and 3% of the patients, respectively. Moreover, cardiac death and moderate-severe PVL were absent. At 1-year, cardiac death and stroke were observed in 3% and 8% of the patients, respectively. In 33.3% of the patients, a larger valve size was implanted compared to the valve size calculated by area sizing. Conclusions. Perimeter sizing with the Myval BE valve leads to substantial use of larger valve sizes and favorable clinical outcomes, with low PPI and the absence of significant PVL. A randomized controlled trial is being planned to prove the superiority of this alternative sizing method.
Collapse
|
15
|
Blasco-Turrión S, Serrador-Frutos A, Jose J, Sengotuvelu G, Seth A, Aldana VG, Sánchez-Luna JP, Gonzalez-Gutiérrez JC, García-Gómez M, Gómez-Herrero J, Aristizabal C, San Román JA, Amat-Santos IJ. Transcatheter Mitral Valve-in-Valve Implantation with the Balloon-Expandable Myval Device. J Clin Med 2022; 11:jcm11175210. [PMID: 36079140 PMCID: PMC9457220 DOI: 10.3390/jcm11175210] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2022] [Revised: 08/15/2022] [Accepted: 08/29/2022] [Indexed: 11/16/2022] Open
Abstract
Background: The vast majority of transcatheter valve-in-valve (ViV) mitral procedures have been reported with the SAPIEN family. We aimed to report the preliminary experience with the Myval balloon-expandable device in this setting. Methods: Multicenter retrospective study of high-risk surgical patients with mitral bioprosthesis degeneration undergoing transcatheter ViV implantation with Myval device. Results: A total of 11 patients from five institutions were gathered between 2019 and 2022 (age 68 ± 7.8, 63% women). The peak and mean transvalvular gradients were 27 ± 5 mmHg and 14.7 ± 2.3 mmHg, respectively, and the predicted neo-left ventricular outflow tract (neo-LVOT) area was 183.4 ± 56 mm2 (range: 171 to 221 mm2). The procedures were performed via transfemoral access in all cases (through echocardiography-guided transeptal puncture (81.8% transesophageal, 11.2% intracardiac)). Technical success was achieved in all cases, with no significant residual mitral stenosis in any of them (peak 7.2 ± 2.7 and mean gradient 3.4 ± 1.7 mmHg) and no complications during the procedure. There were no data of LVOT obstruction, migration, or paravalvular leak in any case. Mean hospital stay was 3 days, with one major vascular complication and no stroke. At 6-month follow-up, there was one case with suboptimal anticoagulation presenting an increase in the transmitral gradients (mean 15 mmHg) that normalized after optimization of the anticoagulation, but no other relevant events. Conclusions: Transseptal ViV mitral implantation with the balloon-expandable Myval device was feasible and safe avoiding redo surgery in high-risk patients with bioprosthesis degeneration.
Collapse
Affiliation(s)
- Sara Blasco-Turrión
- Cardiology Department, Hospital Clínico Universitario de Valladolid, 47003 Valladolid, Spain
| | - Ana Serrador-Frutos
- Cardiology Department, Hospital Clínico Universitario de Valladolid, 47003 Valladolid, Spain
- Centro de Investigación en Red—Enfermedades Cardiovasculares, 28029 Madrid, Spain
| | - John Jose
- Cardiology Unit 2, Christian Medical College Hospital Vellore, Vellore 632004, India
| | | | - Ashok Seth
- Cardiology Department, Fortis Escorts Heart Institute, New Delhi 110025, India
| | - Victor G. Aldana
- Cardiology Department, Clinica Medicadiz, Ibagué 730006, Colombia
| | - Juan Pablo Sánchez-Luna
- Cardiology Department, Hospital Clínico Universitario de Valladolid, 47003 Valladolid, Spain
| | | | - Mario García-Gómez
- Cardiology Department, Hospital Clínico Universitario de Valladolid, 47003 Valladolid, Spain
| | - Javier Gómez-Herrero
- Cardiology Department, Hospital Clínico Universitario de Valladolid, 47003 Valladolid, Spain
| | - Cristhian Aristizabal
- Cardiology Department, Hospital Clínico Universitario de Valladolid, 47003 Valladolid, Spain
| | - J. Alberto San Román
- Cardiology Department, Hospital Clínico Universitario de Valladolid, 47003 Valladolid, Spain
| | - Ignacio J. Amat-Santos
- Cardiology Department, Hospital Clínico Universitario de Valladolid, 47003 Valladolid, Spain
- Correspondence: ; Tel.: +34-983-42-00-26; Fax: +34-983-25-53-05
| |
Collapse
|
16
|
Barki M, Ielasi A, Buono A, Maliandi G, Pellicano M, Bande M, Casilli F, Messina F, Uccello G, Briguglia D, Medda M, Tespili M, Donatelli F. Clinical Comparison of a Novel Balloon-Expandable Versus a Self-Expanding Transcatheter Heart Valve for the Treatment of Patients with Severe Aortic Valve Stenosis: The EVAL Registry. J Clin Med 2022; 11:jcm11040959. [PMID: 35207232 PMCID: PMC8876233 DOI: 10.3390/jcm11040959] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2021] [Revised: 02/05/2022] [Accepted: 02/08/2022] [Indexed: 11/16/2022] Open
Abstract
Background: Transcatheter aortic valve replacement (TAVR) is an effective treatment option for patients with severe, symptomatic AS, regardless of the transcatheter heart valve (THV) implanted. Prior studies demonstrated a higher device success with lower paravalvular leak (PVL) using the balloon-expandable (BE) Sapien/XT THV vs. a self-expanding (SE) THV. However, few data are available on the performance of a novel BE THV. Purpose: to compare early clinical performance and safety of the newly available BE Myval THV (Myval, Meril Life Sciences Pvt. Ltd., India) vs. the commonly used SE (Evolut R, Medtronic) THV. Methods: A single-center, retrospective cohort analysis was performed with 166 consecutive patients undergoing TAVR from March 2019 to March 2021 for severe symptomatic AS treated with either the novel BE Myval or the SE Evolut R (ER) bioprosthesis. The primary endpoint was device success at day 30 according to the Valve Academic Research Consortium-3 (VARC-3). Secondary endpoints included 30-day all-cause mortality, cardiovascular mortality, more than mild PVL, permanent pacemaker implantation (PPI) rates and a composite of all-cause mortality and disabling stroke at 6 months. Results: Among the 166 included patients, 108 patients received the SE ER THV and 58 patients were treated with the BE Myval THV. At baseline, the two groups showed comparable demographic characteristics. The primary composite endpoint of early device success occurred in 55 patients (94.8%) in the BE Myval group and in 90 patients (83.3%) in the SE ER group (OR 3.667, 95% CI 1.094–12.14; p = 0.048). At day 30, the BE Myval THV group exhibited a significantly lower incidence of more than mild PVL (BE Myval 3.45% vs. SE ER 14.8%, OR 0.2, 95% CI 0.05–0.8; p = 0.0338), along with a lower rate of PPI (BE Myval 11% vs. SE ER 24.2%, OR 0.38, 95% CI 0.15–0.99; p = 0.0535). At the 6-month follow-up, the incidence of all-cause mortality and disabling stroke did not significantly differ between the two groups, while the incidence of PPI (BE Myval 11% vs. SE ER 27.5%, OR 0.32, CI 95% 0.1273–0.8; p = 0.02) and ≥moderate PVL (BE Myval 6.9% vs. SE ER 19.8%, OR 0.31, 95% CI 0.1–0.94; p = 0.0396) was significantly lower in the BE Myval group. Conclusions: In patients with severe symptomatic AS undergoing TAVR, the novel Myval BE THV provided a comparable performance to the well-known ER SE THV, and it was associated with a lower rate of PPI and ≥moderate PVL within 30 days and 6 months after the procedure. Randomized, head-to-head comparison trials are needed to confirm our results.
Collapse
Affiliation(s)
- Monica Barki
- Clinical and Interventional Unit, Istituto Clinico Sant’Ambrogio, 20149 Milan, Italy; (M.B.); (A.B.); (G.M.); (M.P.); (M.B.); (F.C.); (F.M.); (G.U.); (D.B.); (M.M.); (M.T.)
| | - Alfonso Ielasi
- Clinical and Interventional Unit, Istituto Clinico Sant’Ambrogio, 20149 Milan, Italy; (M.B.); (A.B.); (G.M.); (M.P.); (M.B.); (F.C.); (F.M.); (G.U.); (D.B.); (M.M.); (M.T.)
- Correspondence:
| | - Andrea Buono
- Clinical and Interventional Unit, Istituto Clinico Sant’Ambrogio, 20149 Milan, Italy; (M.B.); (A.B.); (G.M.); (M.P.); (M.B.); (F.C.); (F.M.); (G.U.); (D.B.); (M.M.); (M.T.)
| | - Gabriele Maliandi
- Clinical and Interventional Unit, Istituto Clinico Sant’Ambrogio, 20149 Milan, Italy; (M.B.); (A.B.); (G.M.); (M.P.); (M.B.); (F.C.); (F.M.); (G.U.); (D.B.); (M.M.); (M.T.)
| | - Mariano Pellicano
- Clinical and Interventional Unit, Istituto Clinico Sant’Ambrogio, 20149 Milan, Italy; (M.B.); (A.B.); (G.M.); (M.P.); (M.B.); (F.C.); (F.M.); (G.U.); (D.B.); (M.M.); (M.T.)
| | - Marta Bande
- Clinical and Interventional Unit, Istituto Clinico Sant’Ambrogio, 20149 Milan, Italy; (M.B.); (A.B.); (G.M.); (M.P.); (M.B.); (F.C.); (F.M.); (G.U.); (D.B.); (M.M.); (M.T.)
| | - Francesco Casilli
- Clinical and Interventional Unit, Istituto Clinico Sant’Ambrogio, 20149 Milan, Italy; (M.B.); (A.B.); (G.M.); (M.P.); (M.B.); (F.C.); (F.M.); (G.U.); (D.B.); (M.M.); (M.T.)
| | - Francesca Messina
- Clinical and Interventional Unit, Istituto Clinico Sant’Ambrogio, 20149 Milan, Italy; (M.B.); (A.B.); (G.M.); (M.P.); (M.B.); (F.C.); (F.M.); (G.U.); (D.B.); (M.M.); (M.T.)
| | - Giuseppe Uccello
- Clinical and Interventional Unit, Istituto Clinico Sant’Ambrogio, 20149 Milan, Italy; (M.B.); (A.B.); (G.M.); (M.P.); (M.B.); (F.C.); (F.M.); (G.U.); (D.B.); (M.M.); (M.T.)
| | - Daniele Briguglia
- Clinical and Interventional Unit, Istituto Clinico Sant’Ambrogio, 20149 Milan, Italy; (M.B.); (A.B.); (G.M.); (M.P.); (M.B.); (F.C.); (F.M.); (G.U.); (D.B.); (M.M.); (M.T.)
| | - Massimo Medda
- Clinical and Interventional Unit, Istituto Clinico Sant’Ambrogio, 20149 Milan, Italy; (M.B.); (A.B.); (G.M.); (M.P.); (M.B.); (F.C.); (F.M.); (G.U.); (D.B.); (M.M.); (M.T.)
| | - Maurizio Tespili
- Clinical and Interventional Unit, Istituto Clinico Sant’Ambrogio, 20149 Milan, Italy; (M.B.); (A.B.); (G.M.); (M.P.); (M.B.); (F.C.); (F.M.); (G.U.); (D.B.); (M.M.); (M.T.)
| | - Francesco Donatelli
- Cardiac Surgery, Department of Cardiothoracic Center, Istituto Clinico Sant’Ambrogio, University of Milan, 20122 Milan, Italy;
| |
Collapse
|
17
|
Elkoumy A, Jose J, Terkelsen CJ, Nissen H, Gunasekaran S, Abdelshafy M, Seth A, Elzomor H, Kumar S, Bedogni F, Ielasi A, Dora SK, Chandra S, Parikh K, Unic D, Wijns W, Baumbach A, Mylotte D, Serruys P, Soliman O. Safety and Efficacy of Myval Implantation in Patients with Severe Bicuspid Aortic Valve Stenosis-A Multicenter Real-World Experience. J Clin Med 2022; 11:jcm11020443. [PMID: 35054137 PMCID: PMC8779274 DOI: 10.3390/jcm11020443] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2021] [Revised: 01/11/2022] [Accepted: 01/13/2022] [Indexed: 11/16/2022] Open
Abstract
Bicuspid aortic valve (BAV) is the most common valvular congenital anomaly and is apparent in nearly 50% of candidates for AV replacement. While transcatheter aortic valve implantation (TAVI) is a recommended treatment for patients with symptomatic severe aortic stenosis (AS) at all surgical risk levels, experience with TAVI in severe bicuspid AS is limited. TAVI in BAV is still a challenge due to its association with multiple and complex anatomical considerations. A retrospective study has been conducted to investigate TAVI's procedural and 30-day outcomes using the Myval transcatheter heart valve (THV) (Meril Life Sciences Pvt. Ltd. Vapi, Gujarat, India) in patients with severe bicuspid AS. Data were collected on 68 patients with severe bicuspid AS who underwent TAVI with the Myval THV. Baseline characteristics, procedural, 30-day echocardiographic and clinical outcomes were collected. The mean age and STS PROM score were 72.6 ± 9.4 and 3.54 ± 2.1. Procedures were performed via the transfemoral route in 98.5%. Major vascular complications (1.5%) and life-threatening bleeding (1.5%) occurred infrequently. No patient had coronary obstruction, second valve implantation or conversion to surgery. On 30-day echocardiography, the mean transvalvular gradient and effective orifice area were 9.8 ± 4.5 mmHg and 1.8 ± 0.4 cm2, respectively. None/trace aortic regurgitation occurred in 76.5%, mild AR in 20.5% and moderate AR in 3%. The permanent pacemaker implantation rate was 8.5% and 30-day all-cause death occurred in 3.0% of cases. TAVI with the Myval THV in selected BAV anatomy is associated with favorable short-term hemodynamic and clinical outcomes.
Collapse
Affiliation(s)
- Ahmed Elkoumy
- Discipline of Cardiology, Saolta Group, Galway University Hospital, Health Service Executive and CORRIB Core Lab, National University of Ireland Galway (NUIG), H91 V4AY Galway, Ireland; (A.E.); (M.A.); (H.E.); (W.W.); (D.M.)
| | - John Jose
- Department of Cardiology, Christian Medical College & Hospital, Vellore 632004, India;
| | | | - Henrik Nissen
- Department of Cardiology, Odense University Hospital, DK-5000 Odense, Denmark;
| | | | - Mahmoud Abdelshafy
- Discipline of Cardiology, Saolta Group, Galway University Hospital, Health Service Executive and CORRIB Core Lab, National University of Ireland Galway (NUIG), H91 V4AY Galway, Ireland; (A.E.); (M.A.); (H.E.); (W.W.); (D.M.)
| | - Ashok Seth
- Fortis Escorts Heart Institute, New Delhi 110025, India;
| | - Hesham Elzomor
- Discipline of Cardiology, Saolta Group, Galway University Hospital, Health Service Executive and CORRIB Core Lab, National University of Ireland Galway (NUIG), H91 V4AY Galway, Ireland; (A.E.); (M.A.); (H.E.); (W.W.); (D.M.)
| | - Sreenivas Kumar
- Department of Cardiology, Apollo Hospitals, Apollo Health City, Jubilee Hills, Hyderabad 500050, India;
| | - Francesco Bedogni
- Department of Cardiology, IRCCS Policlinico San Donato, 20097 Milan, Italy;
| | - Alfonso Ielasi
- Clinical and Interventional Cardiology Unit, Istituto Clinico Sant’Ambrogio, 20149 Milan, Italy;
| | | | - Sharad Chandra
- Department of Cardiology, King George’s Medical University, Lucknow 226003, India;
| | - Keyur Parikh
- Care Institute of Medical Sciences, Ahmedabad 380060, India;
| | - Daniel Unic
- Department of Cardiac and Transplant Surgery, University Hospital Dubrava, 10000 Zagreb, Croatia;
| | - William Wijns
- Discipline of Cardiology, Saolta Group, Galway University Hospital, Health Service Executive and CORRIB Core Lab, National University of Ireland Galway (NUIG), H91 V4AY Galway, Ireland; (A.E.); (M.A.); (H.E.); (W.W.); (D.M.)
- CÚRAM, The SFI Research Centre for Medical Devices, H91 TK33 Galway, Ireland
| | - Andreas Baumbach
- William Harvey Research Institute, Queen Mary University of London and Barts Heart Centre, London EC1M 6BQ, UK;
| | - Darren Mylotte
- Discipline of Cardiology, Saolta Group, Galway University Hospital, Health Service Executive and CORRIB Core Lab, National University of Ireland Galway (NUIG), H91 V4AY Galway, Ireland; (A.E.); (M.A.); (H.E.); (W.W.); (D.M.)
| | - Patrick Serruys
- Discipline of Cardiology, Saolta Group, Galway University Hospital, Health Service Executive and CORRIB Core Lab, National University of Ireland Galway (NUIG), H91 V4AY Galway, Ireland; (A.E.); (M.A.); (H.E.); (W.W.); (D.M.)
- CÚRAM, The SFI Research Centre for Medical Devices, H91 TK33 Galway, Ireland
- National Heart and Lung Institute (NHLI), Imperial College London, London SW7 2AZ, UK
- Correspondence: (P.S.); (O.S.); Tel.: +353-91-493-781 (O.S.)
| | - Osama Soliman
- Discipline of Cardiology, Saolta Group, Galway University Hospital, Health Service Executive and CORRIB Core Lab, National University of Ireland Galway (NUIG), H91 V4AY Galway, Ireland; (A.E.); (M.A.); (H.E.); (W.W.); (D.M.)
- CÚRAM, The SFI Research Centre for Medical Devices, H91 TK33 Galway, Ireland
- Correspondence: (P.S.); (O.S.); Tel.: +353-91-493-781 (O.S.)
| |
Collapse
|
18
|
Santos-Martinez S, Halim J, Castro-Mejía A, De Marco F, Trani C, Martin P, Infusino F, Ancona M, Moreno R, den Heijer P, Nombela-Franco L, Bedogni F, Sardella G, Montorfano M, Revilla-Orodea A, Delgado-Arana JR, Barrero A, Gómez-Salvador I, IJsselmuiden AJJ, Redondo A, Gutiérrez H, Serrador A, Serruys PW, Román JAS, Amat-Santos IJ. Myval versus alternative balloon- and self-expandable transcatheter heart valves: A central core lab analysis of conduction disturbances. Int J Cardiol 2022; 351:25-31. [PMID: 34979152 DOI: 10.1016/j.ijcard.2021.12.049] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/02/2021] [Revised: 12/27/2021] [Accepted: 12/28/2021] [Indexed: 12/29/2022]
Abstract
BACKGROUND Several studies have compared surface electrocardiographic changes following different self-expandable (SE) (Evolut (Medtronic, USA); Acurate (Boston Scientific, USA); Portico (Abbott, USA); and Allegra (NVT, Germany)) and balloon-expandable (BE) Sapien-3 (Edwards Lifesciences, USA) transcatheter heart valves. We aimed to compare these prosthesis with the novel Myval BE prosthesis (Meril Life, India). METHODS Academic European registry of consecutive patients with severe aortic stenosis who received any of the 6 aforementioned valves. Baseline, post-procedural, and discharge 12‑leads electrocardiograms (ECG) were centrally analyzed and compared. RESULTS A total of 1131 patients were included: 135 Myval (11.9%), 290 Sapien-3 (25.6%), 298 Evolut (26.3%), 180 Acurate (15.9%), 125 Portico (11.1%), and 103 Allegra (9.1%). There were no baseline differences in intraventricular conduction disturbances rate. Compared to the novel BE Myval, there were similar procedural and in-hospital outcomes. Similar rates of early new permanent pacemaker implant (PPI) were observed amongst Myval (7.4%), Sapien-3 (13.4%), and Acurate (9.1%), but Evolut, Portico, and Allegra presented significantly higher rates (18.5%, p = 0.003; 29.5% p < 0.001 and 22%, p = 0.001, respectively). Central analysis of ECGs, unraveled significant prolongation of the PR segment with Evolut, Portico and Allegra whereas Evolut, Acurate, and Portico showed significant QRS widening compared to Myval. However, at discharge no differences in PR segment duration were observed while, Evolut, and Portico- but not Acurate, Allegra or Sapien-3 - still presented significant widening of QRS segment compared to Myval. CONCLUSIONS After blinded central ECG analysis, the novel Myval balloon-expandable prosthesis was associated with a low rate of early conduction disturbances.
Collapse
Affiliation(s)
| | | | | | | | - Carlo Trani
- Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy
| | - Pedro Martin
- Hospital Universitario de Gran Canaria Dr Negrin, Gran Canaria, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | | - Alfredo Redondo
- CIBERCV, Hospital Clinico Universitario de Valladolid, Spain
| | | | - Ana Serrador
- CIBERCV, Hospital Clinico Universitario de Valladolid, Spain
| | - Patrick W Serruys
- Department of Cardiology, National University of Ireland, Galway and CORRIB Corelab and Center for Research and Imaging, Galway, Ireland
| | | | | |
Collapse
|
19
|
García-Gómez M, Delgado-Arana JR, Halim J, De Marco F, Trani C, Martin P, Won-Keun K, Montorfano M, den Heijer P, Bedogni F, Sardella G, IJsselmuiden AJJ, Campante Teles R, Aristizabal-Duque CH, Gordillo X, Santos-Martinez S, Barrero A, Gómez-Salvador I, Ancona M, Redondo A, Román JAS, Amat-Santos IJ. Next-generation balloon-expandable Myval transcatheter heart valve in low-risk aortic stenosis patients. Catheter Cardiovasc Interv 2021; 99:889-895. [PMID: 34390296 DOI: 10.1002/ccd.29923] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/05/2021] [Revised: 07/26/2021] [Accepted: 08/02/2021] [Indexed: 11/10/2022]
Abstract
OBJECTIVES We aimed to describe hemodynamic performance and clinical outcomes at 30-day follow-up of the balloon-expandable (BE) Myval transcatheter heart valve (THV) in low-risk patients. BACKGROUND The results of the next-generation BE Myval THV in low-risk aortic stenosis (AS) patients are still unknown. METHODS Retrospective registry performed in nine European centers including patients with low predicted operative mortality risk according to Society of thoracic surgeons (STS) and European system for cardiac operative risk evaluation (EuroSCORE-II) scores. RESULTS Between September 2019 and February 2021, a total of 100 patients (51% males, mean age 80 ± 6.5 years) were included. Mean STS score and EuroSCORE-II were 2.4 ± 0.8% and 2.2 ± 0.7%, respectively. Intermediate sizes were used in 39% (21.5 mm: 8%, 24.5 mm: 15%, 27.5 mm: 15%). There were no cases of valve embolization, coronary artery occlusion, annulus rupture, or procedural death. A definitive pacemaker implantation was needed in eight patients (8%). At 30-day follow-up aortic valve area (0.7 ± 0.2 vs. 2.1 ± 0.6 cm2 ) and mean aortic valve gradient (43.4 ± 11.1 vs. 9.0 ± 3.7 mmHg) improved significantly (p < 0.001). Moderate aortic regurgitation occurred in 4%. Endpoints of early safety and clinical efficacy were 3 and 1%, respectively. CONCLUSIONS Hemodynamic performance and 30-day clinical outcomes of the BE Myval THV in low-risk AS patients were favorable. Longer-term follow-up is warranted.
Collapse
Affiliation(s)
- Mario García-Gómez
- Cardiology Department, CIBERCV, Hospital Clinico Universitario de Valladolid, Valladolid, Spain
| | - Jose Raúl Delgado-Arana
- Cardiology Department, CIBERCV, Hospital Clinico Universitario de Valladolid, Valladolid, Spain
| | - Jonathan Halim
- Cardiology Department, Amphia Hospital Breda, Breda, Netherlands
| | | | - Carlo Trani
- Cardiology Department, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
| | - Pedro Martin
- Cardiology Department, Hospital Universitario de Gran Canaria Dr Negrin, Gran Canaria, Spain
| | - Kim Won-Keun
- Cardiology Department, Kerckhoff Heart Center, Bad Nauheim, Germany
| | - Matteo Montorfano
- Cardiology Department, San Raffaele Scientific Institute, Milan, Italy
| | - Peter den Heijer
- Cardiology Department, Amphia Hospital Breda, Breda, Netherlands
| | | | | | | | | | | | - Ximena Gordillo
- Cardiology Department, CIBERCV, Hospital Clinico Universitario de Valladolid, Valladolid, Spain
| | - Sandra Santos-Martinez
- Cardiology Department, CIBERCV, Hospital Clinico Universitario de Valladolid, Valladolid, Spain
| | - Alejandro Barrero
- Cardiology Department, CIBERCV, Hospital Clinico Universitario de Valladolid, Valladolid, Spain
| | - Itziar Gómez-Salvador
- Cardiology Department, CIBERCV, Hospital Clinico Universitario de Valladolid, Valladolid, Spain
| | - Marco Ancona
- Cardiology Department, San Raffaele Scientific Institute, Milan, Italy
| | - Alfredo Redondo
- Cardiology Department, CIBERCV, Hospital Clinico Universitario de Valladolid, Valladolid, Spain
| | - J Alberto San Román
- Cardiology Department, CIBERCV, Hospital Clinico Universitario de Valladolid, Valladolid, Spain
| | - Ignacio J Amat-Santos
- Cardiology Department, CIBERCV, Hospital Clinico Universitario de Valladolid, Valladolid, Spain
| |
Collapse
|